Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02774681 | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT02061332 | DC Vaccine for Patients With Ductal Carcinoma In Situ(DCIS6) | completed | Phase 1 / Phase 2 | 58 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT01060345 | A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ | terminated | Phase 2 | 20 | University of ChicagoOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT04337658 | Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer(FAVOR) | unknown | Phase 3 | 493 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT01855828 | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | completed | Phase 2 | 50 | Yale UniversityOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT04322331 | Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer | unknown | — | 120 | Peking University People's HospitalOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT00684983 | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2020 | clinicaltrials |
| NCT02879513 | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | unknown | Phase 3 | 290 | RenJi HospitalOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT04316247 | Demographic , Clinicopathological Characteristics and Survival of Breast Cancer | unknown | — | 100 | Assiut UniversityOTHER | 0 | Mar 23, 2020 | clinicaltrials |
| NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 3 | 522 | Shanghai Henlius BiotechINDUSTRY | 0 | Mar 12, 2020 | clinicaltrials |
| NCT04290585 | Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography | completed | N/A | 160 | Fox Chase Cancer CenterOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT00892814 | Partial Breast Versus Whole Breast Irradiation in Elderly Women Operated on for Early Breast Cancer | unknown | N/A | 882 | Danish Breast Cancer Cooperative GroupOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00376688 | Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03109522 | Axillary Reverse Mapping (ARM) Technique(ARM) | unknown | N/A | 130 | McMaster UniversityOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT02766881 | Evaluation of the DCIS Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS(DUCHESS) | completed | — | 281 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT04276337 | Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy | unknown | — | 50 | Samsung Medical CenterOTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT00343109 | Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer | completed | Phase 2 | 38 | University of WashingtonOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT01355393 | Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03110445 | Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus(rVV-740CTA) | withdrawn | Phase 1 | 0 | University Hospital, Basel, SwitzerlandOTHER | 0 | Feb 7, 2020 | clinicaltrials |
| NCT04236310 | A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. | unknown | Phase 2 | 37 | Ruijin HospitalOTHER | 0 | Jan 22, 2020 | clinicaltrials |
| NCT02961790 | Oxybutynin Chloride in Managing Hot Flashes | completed | Phase 3 | 150 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT04225858 | Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy(ASICS) | not yet recruiting | N/A | 340 | The Netherlands Cancer InstituteOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT03348696 | Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients(REaCT-TAPS) | completed | Phase 4 | 124 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT01720602 | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | completed | N/A | 15 | University of WashingtonOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04209010 | Immediate Breast Reconstruction With Acellular Dermal Matrix | completed | — | 44 | Aarhus University HospitalOTHER | 0 | Jan 3, 2020 | clinicaltrials |
| NCT01545648 | Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer | terminated | Phase 2 | 4 | Hope Rugo, MDOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04213898 | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 39 | Henan Cancer HospitalOTHER_GOV | 0 | Dec 30, 2019 | clinicaltrials |
| NCT03964896 | Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy | completed | N/A | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 24, 2019 | clinicaltrials |
| NCT00390455 | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | completed | Phase 3 | 295 | National Cancer Institute (NCI)NIH | 1 | Dec 20, 2019 | clinicaltrials |
| NCT00880503 | Collection of Tissue Samples for Study of Multidrug Resistance | completed | — | 325 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01894451 | Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy | completed | Early Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03811418 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer(ATTILA) | withdrawn | Phase 3 | 0 | iOMEDICO AGINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
| NCT04145947 | Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients | unknown | — | 200 | Peking Union Medical College HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT03185871 | Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses | withdrawn | Phase 2 | 0 | University of Wisconsin, MadisonOTHER | 0 | Nov 15, 2019 | clinicaltrials |
| NCT01783756 | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | completed | Phase 1 / Phase 2 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04158856 | Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer(SHERO) | not yet recruiting | Phase 2 | 60 | xuexin heOTHER | 0 | Nov 12, 2019 | clinicaltrials |
| NCT01641068 | Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms | completed | N/A | 20 | University of WashingtonOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01084057 | Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer | completed | Phase 1 | 56 | City of Hope Medical CenterOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT01753908 | Broccoli Sprout Extract in Treating Patients With Breast Cancer | completed | Early Phase 1 | 30 | Roswell Park Cancer InstituteOTHER | 1 | Oct 31, 2019 | clinicaltrials |
| NCT01869764 | Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer | completed | Phase 2 | 57 | Wake Forest University Health SciencesOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT03855358 | A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) | unknown | Phase 1 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02545023 | Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy | completed | — | 100 | University of Southern CaliforniaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01856543 | Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation | completed | Phase 3 | 143 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02947425 | TARGeted Intraoperative radioTherapy (TARGIT) Registry Database(TARGIT R) | unknown | — | 2,000 | University College, LondonOTHER | 1 | Oct 2, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 14, 2020source: clinicaltrials